Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | STAT3 | P40763 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.44 |
| ▸ | TDP2 | O95551 | 3/20 | 0.37 |
| ▸ | NSD2 | O96028 | 3/20 | 0.37 |
| ▸ | APAF1 | O14727 | 2/20 | 0.37 |
| ▸ | HKDC1 | Q2TB90 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ATG4B | Q9Y4P1 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | GALK1 | P51570 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Triaziquone SCHEMBL10906735 | 0.96 | HTT (0.43) | MAPTHTTTP53STAT3SMN1; SMN2 | |
| Triaziquone SCHEMBL8303 | 0.94 | DNMT1 (0.48) | MAPTHTTTP53STAT3SMN1; SMN2 | |
| Triaziquone SCHEMBL7783197 | 0.92 | MAPT (0.46) | MAPTHTTTP53STAT3SMN1; SMN2 | |
| Triaziquone SCHEMBL7088197 | 0.91 | DNMT1 (0.47) | MAPTHTTTP53STAT3SMN1; SMN2 | |
| Triaziquone SCHEMBL8993238 | 0.91 | DNMT1 (0.47) | MAPTHTTTP53STAT3SMN1; SMN2 | |
| Triaziquone SCHEMBL5054475 | 0.91 | DNMT1 (0.47) | MAPTHTTTP53STAT3SMN1; SMN2 | |
| Triaziquone SCHEMBL8482641 | 0.91 | DNMT1 (0.47) | MAPTHTTTP53STAT3SMN1; SMN2 | |
| Triaziquone SCHEMBL6000230 | 0.91 | DNMT1 (0.47) | MAPTHTTTP53STAT3SMN1; SMN2 | |
| Triaziquone SCHEMBL1538515 | 0.91 | DNMT1 (0.47) | MAPTHTTTP53STAT3SMN1; SMN2 | |
| Triaziquone SCHEMBL9876358 | 0.91 | DNMT1 (0.47) | MAPTHTTTP53STAT3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 183 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122056845-A | Esomeprazole enteric capsule, and preparation method and application thereof | 通化万通药业股份有限公司 | 2026-05-19 | — | — | CN | claimed |
| CN-119432976-A | Freeze-drying reagent for citric acid determination, biochemical analysis chip and determination method thereof | 北京中生金域诊断技术股份有限公司 | 2025-02-14 | — | — | CN | claimed |
| CN-117025645-A | Construction process and application of recombinant avidin | 深圳赛柏生物有限公司 | 2023-11-10 | — | — | CN | claimed |
| EP-3813679-A1 | METHODS AND SYSTEMS FOR SAMPLE COLLECTION | Onegevity Health, LLC (US) | 2021-05-05 | — | — | EP | claimed |
| EP-3050917-B1 | METHOD FOR DEGRADING BIODEGRADABLE RESIN | TOYO SEIKAN GROUP HOLDINGS LTD (JP) | 2019-08-21 | — | — | EP | claimed |
| US-9650489-B2 | Method for degrading biodegradable resin | TOYO SEIKAN GROUP HOLDINGS, LTD. (JP) | 2017-05-16 | — | — | US | claimed |
| US-20160229979-A1 | METHOD FOR DEGRADING BIODEGRADABLE RESIN | TOYO SEIKAN GROUP HOLDINGS, LTD. (JP) | 2016-08-11 | — | — | US | claimed |
| EP-3050917-A1 | METHOD FOR DEGRADING BIODEGRADABLE RESIN | Toyo Seikan Group Holdings, Ltd. (JP) | 2016-08-03 | — | — | EP | claimed |
| CN-122056845-A | Esomeprazole enteric capsule, and preparation method and application thereof | 通化万通药业股份有限公司 | 2026-05-19 | — | — | CN | disclosed |
| US-12427147-B2 | Retinal ganglion cell death inhibitor | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2025-09-30 | — | — | US | disclosed |
| US-12233100-B1 | Composition for improving respiratory health of companion animals | KIM TAE YOON (KR) | 2025-02-25 | — | — | US | disclosed |
| CN-119432976-A | Freeze-drying reagent for citric acid determination, biochemical analysis chip and determination method thereof | 北京中生金域诊断技术股份有限公司 | 2025-02-14 | — | — | CN | disclosed |
| US-20240390508-A1 | HUMAN TRANSFERRIN RECEPTOR BINDING PEPTIDE-DRUG CONJUGATE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-11-28 | — | — | US | disclosed |
| CN-118497183-A | Column gum for enolase purification and purification method of enolase | 金华职业技术学院 | 2024-08-16 | — | — | CN | disclosed |
| EP-1223170-A1 | PYRIMIDINE-5-CARBOXAMIDE COMPOUNDS, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2002-07-17 | — | — | EP | disclosed |
| WO-1999002184-A1 | CAUSATIVE AGENT OF SOW ABORTION AND MORTALITY SYNDROME (SAMS), VACCINE COMPOSITIONS, ANTIBODIES AND METHOD | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1999-01-21 | — | — | WO | disclosed |
| EP-0197554-B1 | TREATMENT OF BIOLOGICAL AND PHARMACEUTICAL PRODUCTS ADSORBED ON A SOLID PHASE WITH VIRUS AND PYROGEN INACTIVATING AGENTS | Armour Pharmaceutical Company (US) | 1990-07-25 | — | — | EP | disclosed |
| US-4673733-A | Treatment of biological and pharmaceutical products adsorbed on a solid phase with virus and pyrogen inactivating agents | ARMOUR PHARMACEUTICAL COMPANY, A CORP OF DE | 1987-06-16 | — | — | US | disclosed |
| EP-0197554-A2 | Treatment of biological and pharmaceutical products adsorbed on a solid phase with virus and pyrogen inactivating agents | Armour Pharmaceutical Company (US) | 1986-10-15 | — | — | EP | disclosed |
| US-4176129-A | FROM LACTIC ACID, ALUMINUM ISOPROPYLATE AND TRIS(HYDROXYMETHYL)AMINOMETHANE | SCHARPER S.P.A. PER L'INDUSTRIA FARMACEUTICA (IT) | 1979-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240390508-A1 | HUMAN TRANSFERRIN RECEPTOR BINDING PEPTIDE-DRUG CONJUGATE | MUSK, TFRC, SLC7A1 | MAPT 2855/4885HTT 1372/4885TP53 3970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.